早期类风湿关节炎中托珠单抗起始治疗与甲氨蝶呤联合泼尼松起始治疗的间接比较
该研究基于U-Act-Early和CAMERA-II两项试验的个体患者数据,间接比较了早期类风湿关节炎中以托珠单抗(TCZ)、TCZ联合甲氨蝶呤(MTX)或MTX联合10 mg泼尼松起始的达标治疗策略。结果显示,TCZ+MTX组24个月DAS28低于MTX+泼尼松组,缓解率更高,但部分效应可能源于TCZ对急性期反应物的特异性影响。
要点
- TCZ+MTX组24个月DAS28较MTX+泼尼松组平均低0.62(95%CI -1.14至-0.10)。
- TCZ+MTX和TCZ组缓解率均高于MTX+泼尼松组(p=0.02/0.05)。
- 排除急性期反应物后,TCZ策略的m-CDAI略高但无统计学差异。
核心结论
- 在早期RA中,基于TCZ的策略较MTX+泼尼松改善了DAS28和缓解率,但至少部分效应可能归因于TCZ对急性期反应物的特异性作用。
研究设计与样本
- 利用U-Act-Early和CAMERA-II两项试验的个体患者数据,间接比较起始TCZ(n=103)、TCZ+MTX(n=106)或MTX+泼尼松(n=117)的达标治疗策略,以起始MTX(n=227)为参照。
主要发现
- 24个月DAS28在TCZ+MTX组低于MTX+泼尼松组,平均差异-0.62(95%CI -1.14至-0.10)。
- TCZ+MTX和TCZ组缓解率分别较MTX+泼尼松组更高(p=0.02和p=0.05)。
- 排除急性期反应物的m-CDAI在TCZ策略中略高于MTX+泼尼松组,但无统计学显著性。
- 其他结局在各策略间无统计学显著差异。
关键数值与推荐
- 主要结局为24个月内的DAS28。
- 缓解采用多种定义评估。
- 采用多水平模型校正试验内聚类、患者随时间重复测量及混杂因素。
临床怎么用
- 对于早期RA,TCZ±MTX达标治疗策略在疾病活动度控制和缓解方面可能优于MTX+10 mg泼尼松,但需注意DAS28的改善部分反映急性期反应物下降,应结合不含急性期反应物的指标综合评估。
局限性
- 为间接比较而非头对头随机对照,存在试验间异质性可能。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the cornerstone of initial treatment for early rheumatoid arthritis (RA). It is not known how this strategy compares with initial treatment with a biological. We therefore compared the effectiveness of tocilizumab (TCZ), or TCZ plus MTX (TCZ+MTX) with MTX plus 10 mg prednisone (MTX+pred), all initiated within a treat-to-target treatment strategy in early RA. METHODS: Using individual patient data of two trials, we indirectly compared tight-controlled treat-to-target strategies initiating TCZ (n=103), TCZ+MTX (n=106) or MTX+pred (n=117), using initiation of MTX (n=227) as reference. Primary outcome was Disease Activity Score assessing 28 joints (DAS28) over 24 months. To assess the influence of acute phase reactants (APRs), a disease activity composite outcome score without APR (ie, modification of the Clinical Disease Activity Index (m-CDAI)) was analysed. Secondary outcomes were remission (several definitions), physical function and radiographic progression. Multilevel models were used to account for clustering within trials and patients over time, correcting for relevant confounders. RESULTS: DAS28 over 24 months was lower for TCZ+MTX than for MTX+Pred (mean difference: -0.62 (95% CI -1.14 to -0.10)). Remission was more often achieved in TCZ+MTX and in TCZ versus MTX+pred (p=0.02/0.05, respectively). Excluding APRs from the disease activity outcome score, TCZ-based strategies showed a slightly higher m-CDAI compared with MTX+pred, but this was not statistically significant. Other outcomes were also not statistically significantly different between the strategies. CONCLUSIONS: In patients with early RA, although TCZ-based strategies resulted in better DAS28 and remission rates compared with MTX+pred, at least part of these effects may be due to a specific effect of TCZ on APRs.
引用
- Verhoeven MM, de Hair MJ, Tekstra J, et al. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. Ann Rheum Dis. 2019. PMID: 31196844. doi:10.1136/annrheumdis-2019-215304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。